Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated the safety and tolerability of anifrolumab, a monoclonal antibody targeting the type I interferon (IFN) receptor, in Japanese patients with moderate-to-severe systemic lupus erythematosus (SLE).
|
30793642 |
2020 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lupus and control CD8+ T cells significantly increased STAT1 mRNA levels after treatment with IFNα.
|
30674474 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High type I IFN activity correlated with levels of IFN-γ and IFN-α and associated with active SLE in most domains: weight loss, fatigue, fever, rash, lymphadenopathy, arthritis, nephritis and haematological manifestations.
|
31036046 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show a novel role for BCAP in promoting TLR-induced IFN-α production in pDC and in systemic lupus erythematosus pathogenesis.
|
30936294 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that conventional dendritic cells (cDCs) from predisease lupus-prone B6.NZM Sle1/Sle2/Sle3 triple congenic (TCSle) mice produce more IL-10 than wild-type congenic cDCs upon TLR stimulation, and this overproduction is prevented by blocking the type I IFN receptor (IFNAR) with specific Abs.
|
31216373 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous reports have described the appearance of systemic lupus erythematosus (SLE) cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly increased in SLE, and an association between SLE and gene variants belonging to IFN downstream pathways has been shown.
|
31190735 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate how IFN responses in SLE keratinocytes contribute to development of CLE.
|
30745462 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunologically, anti-CD40 treatment disrupted multiple processes that contribute to the pathogenesis of systemic lupus erythematosus (SLE), including autoreactive B cell activation, T effector cell function in target tissues, and type I IFN production.
|
31109957 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed at exploring the role of one such gene, α/β-hydrolase domain-containing 6 (ABHD6), in regulation of IFN-α induction in SLE patients.
|
30728209 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, these results suggest that closing the door on targeting the type 1 IFN pathway in SLE may be premature and highlight the emerging question of whether an organ-specific approach toward lupus trials and treatment should be the wave of the future.
|
30776023 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus.
|
31724446 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the current study provides a direct link between type I IFN pathway overactivation and the abnormally high frequency and proinflammatory properties of transitional B cells in active SLE patients, which contributes to the understanding of the roles of type I IFNs and B cells in the pathogenesis of SLE.
|
29563616 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
|
30645203 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, sole upregulation of IFN-α is sufficient to induce SLE, and the double-negative T cells expanded by IFN-α are directly responsible for the organ manifestations, such as lupus skin disease or nephritis.
|
31324723 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: ALB: albumin; ARHGDIB: Rho GDP dissociation inhibitor beta; APOL1: apolipoprotein L1; ATG5: autophagy related 5; ATG7: autophagy related 7; ATG16L2: autophagy related 16 like 2; BECN1: beclin 1; CDKN1B: cyclin dependent kinase inhibitor 1B; CLEC16A, C-type lectin domain containing 16A; CYBB: cytochrome b-245 beta chain; DC: dendritic cell; DRAM1: DNA damage regulated autophagy modulator 1; eQTL: expression quantitative trait loci; GWAS: genome-wide association study; IFNA: interferon alpha; IRGM: immunity related GTPase M; LRRK2: leucine rich repeat kinase 2; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MTMR3: myotubularin related protein 3; LAP" LC3-associated phagocytosis; LN: lupus nephritis; NOD: non-obese diabetic; NPHS2: NPHS2, podocin; PBMC: peripheral blood mononuclear cell; RUBCN: rubicon autophagy regulator; SLE: systemic lupus erythematosus.
|
30755075 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutrophil extracellular traps (NETs) are considered a potential source of antigenic trigger in SLE that can lead to type I IFN gene induction, as well as increased autoantibody production.
|
31130331 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensing self-nucleic acids through toll-like receptors in plasmacytoid dendritic cells (pDCs), and the dysregulated type I IFN production, represent pathogenic events in the development of the autoimmune responses in systemic lupus erythematosus (SLE).
|
31299881 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-γ<sup>+</sup> cells in the CD4<sup>+</sup>CD25<sup>+</sup>T subset fresh-isolated from SLE patients increased slightly, but IFN-γ-producing response to stimulation in CD4<sup>+</sup>CD25<sup>+</sup>T subset of SLE decreased.
|
31019943 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that diseases associated with anti-SSA/Ro autoantibodies, such as systemic lupus erythematosus and Sjögren syndrome, are linked with an upregulation of IFN and type I IFN-stimulated genes, including sialic acid-binding Ig-like lectin 1 (Siglec-1), a receptor on monocytes/macrophages, recent attention has focused on a potential role for IFN and IFN-stimulated genes in the pathogenesis of congenital heart block (CHB).
|
30518570 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.
|
29945921 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IFN-α gene expression was measured by real-time polymerase chain reaction (PCR) assay in 123 Egyptian female patients with SLE and in 100 females as a healthy control group.
|
28659049 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Levels of circulating IFN-α is a heritable risk factor in SLE with causal role in pathogenesis, they differ between SLE patients from different ancestral backgrounds and this information could be important as therapeutics is developed to target this pathway.
|
29775752 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase II studies in SLE suggest beneficial effects of blocking the type I IFN receptor.
|
29889694 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
T cells from patients with SLE carrying the <i>STAT4</i> risk allele rs7574865[T] display an augmented response to IL-12 and IFN-α.
|
29475858 |
2018 |